Relevant bibliographies by topics / Weak key-IV combinations

Contents

  1. Journal articles
  2. Dissertations / Theses

Academic literature on the topic 'Weak key-IV combinations'

Author: Grafiati
Published: 11 December 2022
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Weak key-IV combinations.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Weak key-IV combinations"

1

Roy Choudhury, Shouvik, and Teppei Okumura. "Updated Cosmological Constraints in Extended Parameter Space with Planck PR4, DESI Baryon Acoustic Oscillations, and Supernovae: Dynamical Dark Energy, Neutrino Masses, Lensing Anomaly, and the Hubble Tension." Astrophysical Journal Letters 976, no. 1 (2024): L11. http://dx.doi.org/10.3847/2041-8213/ad8c26.

Full text
Abstract:
Abstract We present updated constraints on cosmological parameters in a 12-parameter model, extending the standard six-parameter ΛCDM by including dynamical dark energy (DE; w 0, w a ), the sum of neutrino masses (∑m ν ), the effective number of non-photon radiation species (N eff), the lensing amplitude scaling (A lens), and the running of the scalar spectral index (α s ). For cosmic wave background (CMB) data, we use the Planck Public Release (PR) 4 (2020) HiLLiPoP and LoLLiPoP likelihoods, Planck PR4+Atacama Cosmology Telescope (ACT) DR6 lensing, and Planck 2018 low-ℓ TT likelihoods, along
APA, Harvard, Vancouver, ISO, and other styles
2

Rugo, H. S., M. Campone, D. Amadori, et al. "Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC)." Journal of Clinical Oncology 27, no. 15_suppl (2009): 1029. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.1029.

Full text
Abstract:
1029 Background: Pac/bev is superior to pac alone as first-line therapy for MBC. Ixa/bev has greater preclinical activity than pac/bev in human tumor models. The primary objective of this trial was to evaluate objective response rates (ORR) of ixa/bev given weekly or every 3 weeks relative to pac/bev as 1st line therapy for women with advanced breast cancer. Methods: Women with measurable disease and no prior chemotherapy for advanced breast cancer (locally advanced or MBC) were randomized in a 3:3:2 ratio to Arm A (ixa 16 mg/m2 IV on days 1, 8 & 15 q28 days/ bev 10 mg/kg IV q 2 wks), Arm
APA, Harvard, Vancouver, ISO, and other styles
3

Sands, B. E., B. G. Feagan, W. J. Sandborn, et al. "OP36 Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study." Journal of Crohn's and Colitis 16, Supplement_1 (2022): i042—i043. http://dx.doi.org/10.1093/ecco-jcc/jjab232.035.

Full text
Abstract:
Abstract Background Preclinical data from a murine model of acute colitis suggest that dual blockade of interleukin(IL)-23 and TNFα more effectively prevented the development of colonic inflammation than each monotherapy. Guselkumab(GUS), an IL-23p19 subunit antagonist, is being studied in inflammatory bowel disease. Golimumab(GOL), a TNFα antagonist, is approved for ulcerative colitis(UC). The objective of this study was to evaluate the efficacy and safety of combination induction therapy with GUS+GOL vs GUS or GOL alone in adults with moderately-to-severely active UC. Methods 214 patients(pt
APA, Harvard, Vancouver, ISO, and other styles
4

Mizutani, Teruyuki, Amrutesh Puranik, Tomoaki Muramatsu, et al. "Abstract 5922: B cell subtype is a predictive and pharmacodynamic biomarkers for combination therapy in stage III-IV melanoma: a simon phase II trial." Cancer Research 85, no. 8_Supplement_1 (2025): 5922. https://doi.org/10.1158/1538-7445.am2025-5922.

Full text
Abstract:
Background: Assessing biomarkers to predict immune-related adverse events (irAEs) is crucial for optimizing melanoma treatment with immune checkpoint inhibitors (ICIs). T and B lymphocytes are key mediators of autoimmunity and are implicated in the development of irAEs. Here we focus on analysis of specific B cell subsets, as predictive and pharmacodynamic biomarkers for irAEs in a phase II trial combining nivolumab (3 mg/kg), ipilimumab(1 mg/ml), and the IL-6 receptor inhibitor tocilizumab (4 mg/kg) in unresectable/advanced stage III/IV melanoma patients. Methods: We analyzed cryopreserved PB
APA, Harvard, Vancouver, ISO, and other styles
5

Chesney, Jason A., Igor Puzanov, Frances A. Collichio, et al. "Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial." Journal for ImmunoTherapy of Cancer 11, no. 5 (2023): e006270. http://dx.doi.org/10.1136/jitc-2022-006270.

Full text
Abstract:
Talimogene laherparepvec (T-VEC) plus ipilimumab has demonstrated greater antitumor activity versus ipilimumab alone, without additional toxicity, in patients with advanced melanoma. Here, we report the 5-year outcomes from a randomized phase II study. These data provide the longest efficacy and safety follow-up for patients with melanoma treated with a combination of an oncolytic virus and a checkpoint inhibitor.Eligible patients with unresectable stage IIIB‒IV melanoma were randomized 1:1 to receive T-VEC plus ipilimumab or ipilimumab alone. T-VEC was administered intralesionally at 106plaqu
APA, Harvard, Vancouver, ISO, and other styles
6

Kubota, Kaoru, Hiroshige Yoshioka, Fumihiro Oshita, et al. "Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer." Journal of Clinical Oncology 35, no. 32 (2017): 3662–70. http://dx.doi.org/10.1200/jco.2017.72.7297.

Full text
Abstract:
Purpose This phase III, randomized, placebo-controlled, double-blind study determined whether motesanib improved progression-free survival (PFS) compared with placebo in combination with paclitaxel and carboplatin (P/C) in East Asian patients with stage IV/recurrent nonsquamous non–small-cell lung cancer. Patients and Methods Patients were randomly assigned (1:1) to receive oral motesanib 125 mg or placebo once daily plus paclitaxel 200 mg/m2 IV and carboplatin area under the concentration-time curve 6 mg/mL ⋅ min IV for up to six 3-week cycles. Random assignment was stratified by epidermal gr
APA, Harvard, Vancouver, ISO, and other styles
7

Xi, Jing, Jingqing Luo, Ciara O’Sullivan, et al. "SYST-13 PHASE II STUDY OF THE COMBINATION OF LIPOSOMAL IRINOTECAN AND PEMBROLIZUMAB FOR TRIPLE-NEGATIVE BREAST CANCER (TNBC) WITH BRAIN METASTASES (BM)." Neuro-Oncology Advances 4, Supplement_1 (2022): i24. http://dx.doi.org/10.1093/noajnl/vdac078.092.

Full text
Abstract:
Abstract BACKGROUND Breast cancer is one of the most common cancers associated with brain metastases (BM). Up to 50% of patients with metastatic triple-negative breast cancer (TNBC) develop BM which portends a poor prognosis, with a median survival of 4.4-7.3 months. There is a lack of effective systemic therapy. Irinotecan is a topoisomerase-1 inhibitor with a response rate of 5-23% in advanced breast cancer. Nal-IRI is an intravenous liposomal formulation of irinotecan, with greater efficacy in tumor growth inhibition and the ability to cross the blood brain barrier (BBB) than irinotecan, re
APA, Harvard, Vancouver, ISO, and other styles
8

Kus, Julianne V., John Kelly, Luc Tessier, Hanjeong Harvey, Dennis G. Cvitkovitch, and Lori L. Burrows. "Modification of Pseudomonas aeruginosa Pa5196 Type IV Pilins at Multiple Sites with d-Araf by a Novel GT-C Family Arabinosyltransferase, TfpW." Journal of Bacteriology 190, no. 22 (2008): 7464–78. http://dx.doi.org/10.1128/jb.01075-08.

Full text
Abstract:
ABSTRACT Pseudomonas aeruginosa Pa5196 produces type IV pilins modified with unusual α1,5-linked d-arabinofuranose (α1,5-d-Araf) glycans, identical to those in the lipoarabinomannan and arabinogalactan cell wall polymers from Mycobacterium spp. In this work, we identify a second strain of P. aeruginosa, PA7, capable of expressing arabinosylated pilins and use a combination of site-directed mutagenesis, electrospray ionization mass spectrometry (MS), and electron transfer dissociation MS to identify the exact sites and extent of pilin modification in strain Pa5196. Unlike previously characteriz
APA, Harvard, Vancouver, ISO, and other styles
9

Hammel, Pascal, Rossana Berardi, Geert-Yan Creemers, et al. "TRYbeCA-1: A randomized, phase III study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441)." Journal of Clinical Oncology 38, no. 15_suppl (2020): TPS4666. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.tps4666.

Full text
Abstract:
TPS4666 Background: Second-line treatment options for advanced pancreatic adenocarcinoma are currently limited. Eryaspase, asparaginase (ASNase) encapsulated in red blood cells (RBCs) is an investigational product under development. Following infusion, asparagine and glutamine are actively transported into RBCs where they are hydrolyzed by the encapsulated ASNase. We have recently reported the outcome of a randomized Phase 2b study inpatients with advanced pancreatic cancer whose disease progressed following first-line treatment(NCT02195180). Eryaspase in combination with gemcitabine monothera
APA, Harvard, Vancouver, ISO, and other styles
10

Hammel, Pascal, Rossana Berardi, Eric Van Cutsem, et al. "TRYbeCA-1: A randomized, phase III study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441)." Journal of Clinical Oncology 38, no. 4_suppl (2020): TPS783. http://dx.doi.org/10.1200/jco.2020.38.4_suppl.tps783.

Full text
Abstract:
TPS783 Background: Second-line treatment options for advanced pancreatic adenocarcinoma are currently limited. Eryaspase, asparaginase (ASNase) encapsulated in red blood cells (RBCs) is an investigational product under development. Following infusion, asparagine and glutamine are actively transported into RBCs where they are hydrolyzed by the encapsulated ASNase. We have recently reported the outcome of a randomized Phase 2b study inpatients with advanced pancreatic cancer whose disease progressed following first-line treatment. Eryaspase in combination with gemcitabine monotherapy or FOLFOX c
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Weak key-IV combinations"

1

Alhamdan, Ali Abdulaziz. "Secure stream cipher initialisation processes." Thesis, Queensland University of Technology, 2014. https://eprints.qut.edu.au/66721/1/Ali%20Abdulaziz%20H_Al%20Hamdan_Thesis.pdf.

Full text
Abstract:
Stream ciphers are symmetric key cryptosystems that are used commonly to provide confidentiality for a wide range of applications; such as mobile phone, pay TV and Internet data transmissions. This research examines the features and properties of the initialisation processes of existing stream ciphers to identify flaws and weaknesses, then presents recommendations to improve the security of future cipher designs. This research investigates well-known stream ciphers: A5/1, Sfinks and the Common Scrambling Algorithm Stream Cipher (CSA-SC). This research focused on the security of the initiali
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Weak key-IV combinations' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography